(Q37221770)

19 August 2017

1 reference

title

Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes (English)

1 reference

19 August 2017

0 references

0 references

J-F Gautier

1

1 reference

19 August 2017

S-P Choukem

series ordinal

2

1 reference

19 August 2017

J Girard

series ordinal

3

1 reference

19 August 2017

publication date

1 February 2008

1 reference

19 August 2017

published in

Diabetes and Metabolism

1 reference

19 August 2017

volume

34 Suppl 2

1 reference

19 August 2017

page(s)

S65-72

1 reference

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

1 reference

7 January 2021

New developments in the incretin concept

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Incretins, insulin secretion and Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Functional GIP receptors are present on adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

GIP biology and fat metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Reduced Incretin Effect in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2973397-4

7 January 2021

10.1016/S1262-3636(08)73397-4

Identifiers

DOI

1 reference

19 August 2017

1 reference